伴CSF1R-Y571D突变的急性髓系白血病细胞系GDM-1的增殖机制

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (1): 44-49.

伴CSF1R-Y571D突变的急性髓系白血病细胞系GDM-1的增殖机制

曹琼¹, 徐凝馨¹, 李小文¹, 吴昊¹, 郝建卿¹, 覃艳红², 李莉^1*

1.山西医科大学基础医学院,山西太原 030001;
2.山西医科大学第二临床医学院血液科, 山西太原 030001

收稿日期:2019-12-16 修回日期:2020-04-28 出版日期:2021-01-05 发布日期:2020-12-30
通讯作者: ^*lili_5076@sxmu.edu.cn
基金资助:
国家自然科学基金青年科学基金(81400139);山西省自然科学基金(2014011039-2)

Proliferation mechanism of acute myeloid leukemia cell line GDM-1 with CSF1R-Y571D mutation

CAO Qiong¹, XU Ning-xin¹, LI Xiao-wen¹, WU Hao¹, HAO Jian-qing¹, QIN Yan-hong², LI Li^1*

1. School of Basic Medicine, Shanxi Medical University, Taiyuan 030001;
2. Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2019-12-16 Revised:2020-04-28 Online:2021-01-05 Published:2020-12-30
Contact: ^*lili_5076@sxmu.edu.cn

摘要/Abstract

摘要： 目的通过蛋白激酶抑制方法研究伴集落刺激因子-1受体(CSF1R)突变的急性髓系白血病细胞系GDM-1的增殖机制。方法按照处理方式不同将GDM-1细胞分为实验组和对照组,将10种不同的蛋白激酶抑制剂作用于实验组,对照组仅做DMSO处理;CCK8法检测细胞增殖抑制情况;Western blot检测蛋白激酶抑制剂作用于GDM-1后,关键激酶的磷酸化水平的改变;细胞因子M-CSF单独或与蛋白激酶抑制剂共同作用于GDM-1细胞,采用CCK8法进行检测细胞增殖水平。结果蛋白激酶抑制分析显示明显抑制GDM-1细胞增殖的药物有dasatinib(IC₅₀=0.01 μmol/L)、bosutinib(IC₅₀=0.07 μmol/L)、linifanib(IC₅₀=0.13 μmol/L)及sorafenib (IC₅₀=0.12 μmol/L)。Western blot显示,与对照组相比,linifanib作用于GDM-1后,SRC、ERK磷酸化水平明显降低(P＜0.01)。在低浓度FBS培养时,细胞因子M-CSF能够刺激伴CSF1R突变型细胞系GDM-1的增殖,其增殖水平为对照组的11.3倍;M-CSF联合bosutinib作用于GDM-1,细胞增殖明显被抑制(P＜0.001),而M-CSF联合HG6-64-1作用于GDM-1,与仅用M-CSF组相比细胞增殖不受影响。结论 GDM-1细胞中CSF1R-Y571D突变使CSF1R活性增高,并主要通过激活Src及MAPK信号通路来促进细胞增殖。

关键词: 蛋白激酶抑制剂, GDM-1, 集落刺激因子1受体, linifanib, bosutinib

Abstract: Objective To explore the proliferation mechanism of acute myeloid leukemia cell line GDM-1 by the method of protein kinase inhibition. Methods GDM-1 cells were divided into experimental group and control group according to different treatment. Experimental group was treated with 10 different protein kinase inhibitors, the control group was treated with DMSO, and the inhibition of cell proliferation was detected by CCK8 method. The phosphorylation level of key protein kinases in GDM-1 after treatment with linifanib, bosutinib, sorafenib were detected by Western blot.GDM-1 cells were treated with cytokine M-CSF alone or combined with protein kinase inhibitors, cell proliferation was detected by CCK8 method. Results Protein kinase inhibition analysis showed that dasatinib (IC₅₀=0.01 μmol/L), bosutinib(IC₅₀=0.07 μmol/L), linifanib (IC₅₀=0.13 μmol/L) and sorafenib (IC₅₀= 0.12 μmol/L) significantly inhibited the proliferation of GDM-1 cells. Western blot analysis showed that the phosphorylation level of Src and ERK in GDM-1 was decreased (P＜0.01) when treated with linifaninb. The proliferation of GDM-1 was 11.3 times as much as that of control group when stimulated with M-CSF. The proliferation of GDM-1 was dramatically inhibited when incubated with the combination of M-CSF and bosutinib (P＜0.001), but it was not significantly inhibited when incubated with M-CSF plus HG6-64-1. Conclusions CSF1R-Y571D mutation of GDM-1 cells increases the activity of CSF1R, and promotes cell proliferation by activating Src and MAPK signaling pathways.

Key words: protein kinase inhibitor, GDM-1, colony stimulating factor-1 receptor, linifanib, bosutinib

中图分类号:

R733.71

曹琼, 徐凝馨, 李小文, 吴昊, 郝建卿, 覃艳红, 李莉. 伴CSF1R-Y571D突变的急性髓系白血病细胞系GDM-1的增殖机制[J]. 基础医学与临床, 2021, 41(1): 44-49.

CAO Qiong, XU Ning-xin, LI Xiao-wen, WU Hao, HAO Jian-qing, QIN Yan-hong, LI Li. Proliferation mechanism of acute myeloid leukemia cell line GDM-1 with CSF1R-Y571D mutation[J]. Basic & Clinical Medicine, 2021, 41(1): 44-49.

参考文献

[1] Kayser S, Levis MJ. Advances in targeted therapy for acute myeloid leukaemia[J]. Br J Haematol, 2018, 180:484-500.
[2] Tian Y, Wang G, Hu Q, et al. AML1/ETO trans-activa-tes c-KIT expression through the long range interaction between promoter and intronic enhancer[J]. J Cell Biochem. 2018,119:3706-3715.
[3] Ronchini C, Brozzi A, Riva L,et al. PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias[J]. Leukemia, 2017, 31:1975-1986.
[4] Marschalek . MLL leukemia and future treatment strategies[J]. Arch Pharm (Weinheim), 2015, 348:221-228.
[5] 弓晓媛, 刘凯奇, 魏述宁,等. MLL基因重排成人急性髓系白血病的特征和预后分析[J]. 中华血液学杂志, 2018, 39:9-14.
[6] Cortes JE, Gambacorti-Passerini C, Deininger MW,et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial[J]. J Clin Oncol, 2018, 36:231-237.
[7] Zhong WZ, Wang Q, Mao WM,et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19:139-148.
[8] Cannarile MA, Weisser M, Jacob W, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy[J]. J Immunother Cancer, 2017, 5:53-53.
[9] Achkova D, Maher J. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer[J]. Biochem Soc Trans, 2016, 44:333-341.
[10] Niehus SE, Tran DDH, Mischak M, et al. Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib[J]. Cell Signal, 2018, 51:191-198.
[11] Patsialou A Wang Y, Pignatelli J, et al. Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells[J]. Oncogene, 2015, 34:2721-2731.
[12] Okugawa Y, Toiyama Y, Ichikawa T, et al. Colony-stimulating factor-1 and colony stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer[J]. Int J Oncol, 2018, 53: 737-749.
[13] Inamura K, Shigematsu Y, Ninomiya H, et al. CSF1R-expressing tumor-associated macrophages, smoking and survival in lung adenocarcinoma: analyses using quantita-tive phosphor-integrated dot staining[J]. Cancers (Basel), 2018, 10:1-15.
[14] Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells[J]. Leukemia,2009,23: 477-485.
[15] Forbes SA, Beare D, Boutselakis H,et al. COSMIC: somatic cancer genetics at high-resolution[J]. Nucleic Acids Res, 2017, 45: D777-D783.
[16] Sondka Z, Bamford S, Cole CG, et al. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers[J]. Nat Rev Cancer, 2018,18:696-705.
[17] Chase A, Schultheis B, Kreil S, et al. Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1[J]. Leukemia, 2009, 23: 358-364.
[18] Makishima H, Sugimoto Y, Szpurka H, et al. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors[J]. Leukemia, 2012, 26: 1547-1554.
[19] Chen J, Guo J, Chen Z,et al.Linifanib (ABT-869) potentiates the efficacy of chemotherapeutic agents through the suppression of receptor tyrosine Kinase-mediated AKT/mTOR signaling pathways in gastric cancer[J]. Sci Rep, 2016, 6:29382.doi:10.1038/srep29382.
[20] Albert DH, Tapang P, Magoc TJ, et al.Preclinical activity of ABT-869, amultitargeted receptor tyrosine kinaseinhibitor[J]. Mol Cancer Ther,2006,5:995-1006.
[21] Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer[J]. Acta Pharmacol Sin,2017, 8: 614-622.